Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29689
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorCLE, Diego V.-
dc.contributor.authorATTA, Elias H.-
dc.contributor.authorDIAS, Danielle S. P.-
dc.contributor.authorLIMA, Carlos B. L.-
dc.contributor.authorBONDUEL, Mariana-
dc.contributor.authorSCIUCCATI, Gabriela-
dc.contributor.authorMEDEIROS, Larissa A.-
dc.contributor.authorOLIVEIRA, Michel M. de-
dc.contributor.authorFONSECA, Patricia B. Blum-
dc.contributor.authorSAAD, Sara T. O.-
dc.contributor.authorHAMERSCHLAK, Nelson-
dc.contributor.authorSALVINO, Marco A.-
dc.contributor.authorGARANITO, Marlene P.-
dc.contributor.authorPAZIN-FILHO, Antonio-
dc.contributor.authorSCHEINBERG, Phillip-
dc.contributor.authorCALADO, Rodrigo T.-
dc.date.accessioned2018-11-21T17:09:38Z-
dc.date.available2018-11-21T17:09:38Z-
dc.date.issued2018-
dc.identifier.citationANNALS OF HEMATOLOGY, v.97, n.11, p.2039-2046, 2018-
dc.identifier.issn0939-5555-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29689-
dc.description.abstractIn a prospective randomized study, treatment for aplastic anemia (AA) with rabbit antithymocyte globulin (r-ATG) and cyclosporine showed inferior hematological response and survival in comparison to horse antithymocyte globulin (h-ATG) and cyclosporine. However, h-ATG was discontinued in most Asian, South American, and European countries, where r-ATG became the only ATG formulation available. We retrospectively evaluated consecutive patients with acquired AA who received either rabbit (n=170) or horse (n=85) ATG and cyclosporine for first-line treatment from 1992 to 2014 in seven referral centers in Brazil and Argentina. Overall response at 3months was 17% (95%CI, 11-23%) for r-ATG and 44% (95%CI, 33-55%) for h-ATG (p<0.001). At 6months, it was 31% (95%CI, 34-39%) for r-ATG and 59% (95%CI, 48-69%) for h-ATG (p<0.001). Overall survival at 5years was 57% (95%CI, 47-65%) for r-ATG and 80% (95%CI, 69-87%) for h-ATG (log-rank=0.001). Relapse was significantly higher in patients receiving h-ATG (28%; 95%CI, 17-43%) as compared to r-ATG (9.4%; 95%CI, 4-21%; log-rank, p=0.01). The type of ATG was the only factor associated with both response and survival. The r-ATG dose varied from 1 to 5mg/kg/day, but it did not correlate with outcomes. In summary, this is the largest multicenter study comparing the two ATG formulations in AA. Our results indicate that the dose of r-ATG does not influence hematologic response or survival in first-line therapy for acquired AA. Considering the toxicity and costs of r-ATG, our findings challenge its aggregate benefit to cyclosporine therapy and further strengthen that h-ATG should remain standard therapy in AA.-
dc.language.isoeng-
dc.publisherSPRINGER-
dc.relation.ispartofAnnals of Hematology-
dc.rightsrestrictedAccess-
dc.subjectAplastic anemia-
dc.subjectAntithymocyte globulin-
dc.subjectATG dose-
dc.subjectResponse-
dc.subjectSurvival-
dc.subject.otheranti-thymocyte globulin-
dc.subject.otherhematopoietic progenitor cells-
dc.subject.otherbone-marrow-transplantation-
dc.subject.otherregulatory t-cells-
dc.subject.otherimmunosuppressive therapy-
dc.subject.othercyclosporine-a-
dc.subject.othersingle-center-
dc.subject.otherhorse-
dc.subject.otherefficacy-
dc.subject.otherchildren-
dc.titleRabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study-
dc.typearticle-
dc.rights.holderCopyright SPRINGER-
dc.identifier.doi10.1007/s00277-018-3416-4-
dc.identifier.pmid29978284
dc.subject.wosHematology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalCLE, Diego V.:Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Internal Med, Ribeirao Preto, SP, Brazil-
hcfmusp.author.externalATTA, Elias H.:Brazilian Natl Canc Inst, CEMO, Rio De Janeiro, RJ, Brazil; Hemorio, Haematopoiet Stem Cell Program, Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalDIAS, Danielle S. P.:Brazilian Natl Canc Inst, CEMO, Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalLIMA, Carlos B. L.:Brazilian Natl Canc Inst, CEMO, Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalBONDUEL, Mariana:Hosp Pediat Prof Dr Juan P Garrahan, Serv Hematol Oncol, Buenos Aires, DF, Argentina-
hcfmusp.author.externalSCIUCCATI, Gabriela:Hosp Pediat Prof Dr Juan P Garrahan, Serv Hematol Oncol, Buenos Aires, DF, Argentina-
hcfmusp.author.externalMEDEIROS, Larissa A.:Univ Fed Parana, Bone Marrow Transplantat Unit, Curitiba, PR, Brazil-
hcfmusp.author.externalOLIVEIRA, Michel M. de:Univ Fed Parana, Bone Marrow Transplantat Unit, Curitiba, PR, Brazil-
hcfmusp.author.externalFONSECA, Patricia B. Blum:Darcy Vargas Childrens Hosp, Sao Paulo, Brazil-
hcfmusp.author.externalSAAD, Sara T. O.:Univ Estadual Campinas, Hemoctr, Hematol & Transfus Med Ctr, Campinas, SP, Brazil-
hcfmusp.author.externalHAMERSCHLAK, Nelson:Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil-
hcfmusp.author.externalSALVINO, Marco A.:Univ Fed Bahia, Bone Marrow Transplantat Unit, Salvador, BA, Brazil-
hcfmusp.author.externalPAZIN-FILHO, Antonio:Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Internal Med, Ribeirao Preto, SP, Brazil-
hcfmusp.author.externalCALADO, Rodrigo T.:Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Internal Med, Ribeirao Preto, SP, Brazil-
hcfmusp.description.beginpage2039-
hcfmusp.description.endpage2046-
hcfmusp.description.issue11-
hcfmusp.description.volume97-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000447952400003-
hcfmusp.origem.id2-s2.0-85049565277-
hcfmusp.publisher.cityNEW YORK-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAfable MG, 2011, HAEMATOL-HEMATOL J, V96, P1269, DOI 10.3324/haematol.2011.042622-
hcfmusp.relation.referenceAtta EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107155-
hcfmusp.relation.referenceAtta EH, 2010, ANN HEMATOL, V89, P851, DOI 10.1007/s00277-010-0944-y-
hcfmusp.relation.referenceBrennan DC, 1999, TRANSPLANTATION, V67, P1011, DOI 10.1097/00007890-199904150-00013-
hcfmusp.relation.referenceCAMITTA BM, 1975, BLOOD, V45, P355-
hcfmusp.relation.referenceChuncharunee S, 2016, INT J HEMATOL, V104, P454, DOI 10.1007/s12185-016-2053-8-
hcfmusp.relation.referenceFeng XM, 2008, BLOOD, V111, P3675, DOI 10.1182/blood-2008-01-130146-
hcfmusp.relation.referenceFlynn J, 2003, BRIT J HAEMATOL, V122, P289, DOI 10.1046/j.1365-2141.2003.04400.x-
hcfmusp.relation.referenceHUANG AT, 1987, P NATL ACAD SCI USA, V84, P5942, DOI 10.1073/pnas.84.16.5942-
hcfmusp.relation.referenceJeong DC, 2014, HAEMATOLOGICA, V99, P664, DOI 10.3324/haematol.2013.089268-
hcfmusp.relation.referenceKaufman DW, 1991, DRUG ETIOLOGY AGRANU-
hcfmusp.relation.referenceKekre N, 2017, HAEMATOLOGICA, V102, P1291, DOI 10.3324/haematol.2017.164459-
hcfmusp.relation.referenceKillick SB, 2000, BRIT J HAEMATOL, V108, P582, DOI 10.1046/j.1365-2141.2000.01853.x-
hcfmusp.relation.referenceLi XX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056648-
hcfmusp.relation.referenceLopez M, 2006, J AM SOC NEPHROL, V17, P2844, DOI 10.1681/ASN.2006050422-
hcfmusp.relation.referenceMaciejewski JP, 2002, BLOOD, V99, P3129, DOI 10.1182/blood.V99.9.3129-
hcfmusp.relation.referenceMahapatra M, 2015, J Assoc Physicians India, V63, P30-
hcfmusp.relation.referenceMarsh JC, 2012, BLOOD, V119, P5391, DOI 10.1182/blood-2012-02-407684-
hcfmusp.relation.referenceMaschan A, 1999, BRIT J HAEMATOL, V106, P967, DOI 10.1046/j.1365-2141.1999.01650.x-
hcfmusp.relation.referenceNaparstek E, 1999, EXP HEMATOL, V27, P1210, DOI 10.1016/S0301-472X(99)00052-1-
hcfmusp.relation.referenceRosenfeld S, 2003, JAMA-J AM MED ASSOC, V289, P1130, DOI 10.1001/jama.289.9.1130-
hcfmusp.relation.referenceScheinberg P, 2006, BRIT J HAEMATOL, V133, P606, DOI 10.1111/j.1365-2141.2006.06085.x-
hcfmusp.relation.referenceScheinberg P, 2007, BLOOD, V109, P3219, DOI 10.1182/blood-2006-09-045625-
hcfmusp.relation.referenceScheinberg P, 2012, BLOOD, V120, P1185, DOI 10.1182/blood-2011-12-274019-
hcfmusp.relation.referenceScheinberg P, 2012, BLOOD, V119, P345, DOI 10.1182/blood-2011-05-352328-
hcfmusp.relation.referenceScheinberg P, 2011, NEW ENGL J MED, V365, P430, DOI 10.1056/NEJMoa1103975-
hcfmusp.relation.referenceScheinberg P, 2009, HAEMATOL-HEMATOL J, V94, P348, DOI 10.3324/haematol.13829-
hcfmusp.relation.referenceShetty M, 2016, J CLIN DIAGN RES, V10, pOC15, DOI 10.7860/JCDR/2016/16144.7952-
hcfmusp.relation.referenceShin SH, 2013, ANN HEMATOL, V92, P817, DOI 10.1007/s00277-013-1674-8-
hcfmusp.relation.referenceSocie G, 2000, SEMIN HEMATOL, V37, P91-
hcfmusp.relation.referenceSuzuki T, 2016, INT J HEMATOL, V104, P446, DOI 10.1007/s12185-016-2046-7-
hcfmusp.relation.referenceTownsley DM, 2017, NEW ENGL J MED, V376, P1540, DOI 10.1056/NEJMoa1613878-
hcfmusp.relation.referenceVallejo C, 2015, ANN HEMATOL, V94, P947, DOI 10.1007/s00277-015-2305-3-
hcfmusp.relation.referenceYoshimi A, 2013, BLOOD, V121, P860, DOI 10.1182/blood-2012-10-461509-
hcfmusp.relation.referenceYoung NS, 2008, CURR OPIN HEMATOL, V15, P162, DOI 10.1097/MOH.0b013e3282fa7470-
hcfmusp.relation.referenceYoung NS, 2006, BLOOD, V108, P2509, DOI 10.1182/blood-2006-03-010777-
hcfmusp.relation.referenceZheng YZ, 2006, EXP HEMATOL, V34, P826, DOI 10.1016/j.exphem.2006.03.017-
dc.description.indexMEDLINE-
dc.identifier.eissn1432-0584-
hcfmusp.citation.scopus11-
hcfmusp.scopus.lastupdate2022-06-16-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr


Files in This Item:
File Description SizeFormat 
art_CLE_Rabbit_antithymocyte_globulin_dose_does_not_affect_response_2018.PDF
  Restricted Access
publishedVersion (English)587.16 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.